High dose chemotherapy with peripheral blood stem cell support in limited small cell lung cancer Sinirli kucuk hucreli akciger kanserinde periferal kan kok hucre destegi ile yuksek doz kemoterapi uygulanimi
Bulletin of Gulhane Military Medical Academy, cilt.40, sa.1, ss.47-50, 1998 (Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 40 Sayı: 1
- Basım Tarihi: 1998
- Dergi Adı: Bulletin of Gulhane Military Medical Academy
- Derginin Tarandığı İndeksler: Scopus
- Sayfa Sayıları: ss.47-50
- Anahtar Kelimeler: High Dose Chemotherapy, Peripheral Blood Stem Cell Transplantation, Small Cell Lung Cancer
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Although limited small cell lung cancer (SCLC) is chemosensitive, rarely can it be curable. Highly significant dose-response relation reported at clinical studies in these patients shows that overall survival can be increased by high dose chemotherapy. So a study was planned related to high dose chemotherapy with peripheral blood stem cell support followed by thoracal and prophylactic cranial radiotherapy in SCLC; and the first case to whom this protocol was applied was reported in this article. 6 courses of chemotherapy (cisplatin, etoposide, ifosfamid) and thoracal radiotherapy in dose of 300 cGy x 10 were given to 54 years old male with SCLC limited to right chest in December 1995. After getting complete response to that therapy, the case was admitted to high dose chemotherapy and peripheral blood stem cell transplantation protocol. 6.85 x 108/kg mononuclear cells and 10.1 x 106/kg CD34 (+) cells were collected totally by progenitor cell mobilisation procedure with 10 μgr/kg/day G-CSF. ICE chemotherapy (ifosfamide 12 gr/m2), carboplatin 1.2 gr/m2 and etoposide 1.2 gr/m2; in 6 days) was administered. Neutrophil (> 500/mm3) and platelet (>50.000/mm3) engraftments were achieved on 13(th) and 19(th) days of reinfusuon, respectively. We did not observe any serious toxicity findings except nausea- vomiting (grade 2), mucositis (grade 1) and alopesia (grade 4). 4 erythrocyte and 4 platelet transfusions totally were given and prophylactic cranial radiotherapy in dose of 300 cGy x 10 was applied to the patient in posttransplant 2(nd) month. We observed relaps in his posttransplant 75(th) day and administered paclitaxel (135 mg/m2) and farmarubisin (60 mg/m2), on posttransplant 110(th) days, he is on second course of chemotherapy.